Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.Georgina V. Long, F. Stephen Hodi, John M. Kirkwood et al.|Journal of Clinical Oncology|2016Cited by 110
Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Rogerio I. Neves et al.|Journal of Clinical Oncology|2017Cited by 55
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.Robert L. Ferris, Yukihiro Nishiyama, Richard S. Ungerleider et al.|Journal of Clinical Oncology|2014Cited by 30
Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.Robert Hans Ingemar Andtbacka, Kenneth F. Grossmann, Merrick I. Ross et al.|Journal of Clinical Oncology|2016Cited by 19